CSI Market
Sign In | Register

Madrigal Pharmaceuticals Inc (MDGL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MDGL quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Madrigal Pharmaceuticals Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-288.28
Depreciation & amortization1.51
Amortization of Other Assets1.60
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-36.98
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation98.13
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt2.78
Increase Decrease Accrued Contract And Research Costs-
Paid In Kind Interest Related Party Debt-
Increase Decrease In Accrued Interest Net Of Interest Received5.97
Operating Lease Right Of Use Asset Periodic Reduction Increase3.21
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-80.65
Increase (Decrease) in Accounts Payable, Trade5.28
Increase (Decrease) in Accrued Liabilities131.90
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-34.02
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-189.55
Investing Activities
Capital Expenditures-3.47
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities1,083.30
Payments to Acquire Available-for-sale Securities, Debt-1,047.51
Real Estate Investments0.00
Proceeds From Sale Of Property Plant And Equipment And Other Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities32.32
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-10.41
Long-term debt - borrowings350.00
Long-term debt - repayments-121.66
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net38.06
Proceeds From Stock Sale To Related Parties-
Proceeds From Issuance Of Common Stock To Related Parties-
Proceeds From Advances From Related Party-
Proceeds From Issuance Or Sale Of Equity Net-
Proceeds From Issuance Of Common Stock Including Exercise Of Common Stock Options-
Proceeds From The Sale Of Related Party Stock And Exercise Of Common Stock Options Net Of Transaction Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities255.98
Effect of exchange rate on cash flow0.01
Discontinued operations0.00
Free Cash Flow-193.02
Total Cash Flow98.76
4 historic quarters locked

Sign in to unlock the full Madrigal Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Madrigal Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 19, 2026
  • Source: mdgl-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-009514

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License